FrancophonIA/ELRC3.0 huggingface dataset:
English: • In 743 patients not satisfactorily controlled on metformin alone, HbA1c levels fell by around 0.7 percentage points (from around 8.1% to around 7.4%) in patients adding saxagliptin compared with a rise of around 0.1 percentage points in patients adding placebo.
Maltese: • F'743 pazjent li ma kinux ikkontrollati b'mod sodisfaċenti fuq il-metformina biss, il-livelli ta' HbA1c naqsu b'madwar 0.7 punti perċentwali (minn madwar 8.1% għal madwar 7.4%) f'pazjenti li żiedu s-saksagliptina meta mqabbel ma' żieda ta' madwar 0.1 punti perċentwali f'pazjenti li żiedu lplaċebo.
English: The main measure of effectiveness was the reduction in blood levels of a substance called glycosylated haemoglobin (HbA1c) after 24 weeks of treatment.
Maltese: Il-kejl ewlieni tal-effikaċja kien it-tnaqqis fil-livelli tad-demm ta' sustanza msejħa emoglobina glikosilata (HbA1c) wara 24
English: By increasing levels of incretin hormones in the blood, saxagliptin stimulates the pancreas to produce more insulin when blood glucose levels are high.
Maltese: Billi jżid il-livelli ta' ormoni ta' inkretin fid-demm, saksagliptin jistimula lillfrixa biex tipproduċi aktar insulina meta l-livelli ta' glukożju fid-demm ikunu għoljin.
English: This is a summary of the European public assessment report (EPAR) for Onglyza.
Maltese: Dan huwa sommarju tar-rapport pubbliku Ewropew ta
English: These hormones are released after a meal and stimulate the pancreas to produce insulin.
Maltese: Dawn l-ormoni jiġu rilaxxati wara ikla u jistimulaw lillfrixa biex tipproduċi l-insulina.
English: Saxagliptin given on its own has also been shown to be more effective than placebo at controlling blood glucose in four studies: in patients given saxagliptin HbA1c levels fell by around 0.5 percentage points more than in patients given placebo.
Maltese: Intwera wkoll li s-saksagliptina mogħtija waħedha hija iktar effettiva mill-plaċebo fil-kontroll talglukożju fid-demm f'erba' studji: f'pazjenti li ngħataw is-saksagliptina l-livelli ta' HbA1c naqsu b'madwar 0.5 punti perċentwali iktar mill-pazjenti li ngħataw il-plaċebo.
English: • In 768 patients not satisfactorily controlled on a sulphonylurea, HbA1c levels fell by around 0.6 percentage points in patients adding saxagliptin compared with a rise of around 0.1 percentage points in patients who added placebo.
Maltese: • F'768 pazjent li ma kinux ikkontrollati b'mod sodisfaċenti bis-sulfonilurea, il-livelli ta' HbA1c naqsu b'madwar 0.6 punti perċentwali f'pazjenti li żiedu s-saksagliptina meta mqabbel ma' żieda ta' madwar 0.1 punti perċentwali f'pazjenti li żiedu l-plaċebo.
English: • In 457 patients not satisfactorily controlled on insulin (with or without metformin), HbA1c levels fell by around 0.7 percentage points in patients adding saxagliptin compared with a fall of around 0.3 percentage points in patients adding placebo.
Maltese: • F'457 pazjent li ma kinux ikkontrollati b'mod sodisfaċenti bl-insulina (flimkien jew mingħajr ilmetaformina), il-livelli ta' HbA1c naqsu b'madwar 0.7 punti perċentwali f'pazjenti li żiedu ssaksagliptina meta mqabbel ma' tnaqqis ta' madwar 0.3 punti perċentwali f'pazjenti li żiedu lplaċebo.
English: However, the results were not considered to be clinically relevant and the company withdrew its application for the use of saxagliptin as an initial combination medicine in previously untreated patients.
Maltese: Madankollu, ir-riżultati ma tqiesux relevanti klinikament u lkumpanija rtirat l-applikazzjoni tagħha għall-użu tas-saksagliptina bħala mediċina ta' kombinazzjoni inizjali f'pazjenti li qatt ma kienu ngħataw kura.
English: Onglyza must not be used in people who are hypersensitive (allergic) to saxagliptin, any of the other ingredients or who have ever had a serious allergic reaction to any DPP-4 inhibitor.
Maltese: Onglyza m'għandux jintuża f'nies li huma ipersensittivi (allerġiċi) għas-saksagliptina, għal kwalunkwe ingredjent ieħor jew li qatt kellhom reazzjoni allerġika gravi għal kwalunkwe inibitur DPP-4.
English: For the full list of all side effects reported with Onglyza, see the package leaflet.
Maltese: Għal-lista sħiħa tal-effetti sekondarji kollha rrappurtati bi Onglyza, ara l-fuljett ta
English: ATCvet code: QP54AB52.
Maltese: QP54AB52
English: Intervet Productions Rue de Lyons 27460 Igoville FRANCE
Maltese: Intervet Productions Rue de Lyons 27460
English: 6.2 Major incompatibilities
Maltese: .2 Inkompatibilitajiet
English: BRAVECTO PLUS spot-on solution
Maltese: BRAVECTO PLUS soluzzjoni spot-on
English: Pharmacotherapeutic group: Antiparasitic products, insecticides and repellents, endectocides, milbemycins.
Maltese: Grupp farmako-terapewtiku:Prodotti antiparasitarji, insettiċidi u ripellanti, endectocides, milbemycins.
English: Intervet International B. V. Wim de Körverstraat 35 5831 AN Boxmeer The Netherlands
Maltese: Wim de Körverstraat 35 5831 AN Boxmeer
English: Macrocyclic lactones including moxidectin have been shown to be substrates for p-glycoprotein.
Maltese: Lactones macrocyclic inklus moxidectin kienu murija li huma substrat għal p-glycoproteins.
English: Intervet UK Limited Walton Manor, Walton, Milton Keynes, Buckinghamshire, MK7 7AJ United Kingdom
Maltese: Walton Manor, Walton, Milton Keynes, Buckinghamshire, MK7 7AJ
English: Fluralaner is an acaricide and insecticide.
Maltese: Fluralaner huwa arakiċida u insettiċidia.
English: Each cardboard box contains 1 or 2 pipettes.
Maltese: Kull kaxxa tal-kartun fiha 1 jew 2 pipetti.
English: Each ml of solution contains 280 mg fluralaner and 14 mg moxidectin.
Maltese: Kull ml ta`soluzzjoni fih 280mg fluralaner u 14mg moxidectin.
English: Method of administration
Maltese: Metodu ta`amministrazzjoni
English: For the treatment of infections with intestinal roundworm (4th stage larvae, immature adults and adults of Toxocara cati) and hookworm (4th stage larvae, immature adults and adults of Ancylostoma tubaeforme).
Maltese: Għat-trattament ta' infezzjonijiet b'roundworms intestinali (stadju larvali 4, adulti immaturi u adulti tat-Toxocara cati) u hookworm (stadju larvali 4, adulti immaturi u adulti tal-Ancylostoma tubaeforme)
English: Date of first authorisation: 08/05/2018
Maltese: DATA TA' L-EWWEL AWTORIZZAZZJONI / TIĠDID TAL-AWTORIZZAZZJONI Data tal-ewwel awtorizazzjoni: 08/05/2018
English: Milton Keynes Buckinghamshire MK7 7AJ
Maltese: Milton Keynes Buckinghamshire
English: Lot:{number}
Maltese: Lott:{numru}
English: Moxidectin, a semisynthetic derivative of nemadectin, belongs to the milbemycin group of macrocyclic lactones (avermectins being the other) and has parasiticidal activity against a range of internal and external parasites (including ear mites (Otodectes cynotis)).
Maltese: Moxidectin, derivattiv sintetiku tan- nemadectin, jappartjeni għall-grupp tal-milbemycin ta` macrocyclic lactones (l-ieħor huwa avermectin) u għandu attivita parassitiċida kontra firxa ta`parassiti interni u esterni (inkluż id-dud tal-widnejn (Otodectes cynotis)).
English: In in vitro bio-assays, fluralaner is not affected by proven field resistances against amidines (tick), organophosphates (tick), cyclodienes (tick, flea), phenylpyrazoles (tick, flea), benzophenyl ureas (tick), and pyrethroids (tick).
Maltese: F`bio-assays in vitro, fluralaner mhuhiex affetwat minn reżistenzi pruvati fil-post kontra amidines (qurdien), organophosphates (qurdien), cyclodienes (qurdien, briegħed), phenylpyrazoles (qurdien, briegħed), benzophenyl ureas (qurdien), u pyrethroids (qurdien).
English: FRANCE
Maltese: Olanda
English: Fluralaner is readily systemically absorbed from the topical administration site, reaching maximum concentrations in plasma between 3 and 21 days after administration.
Maltese: Fluralaner huwa assorbit malajr sistematikament mill-post ta` amministrazzjoni topikali, li jilħaq ilkonċentrazzjoni massima fil-plasma madwar 3 u 21 ġurnata wara li jiġi amministrat.
English: Fluralaner is a potent inhibitor of parts of the arthropod nervous system by acting antagonistically on ligand-gated chloride channels (GABA-receptor and glutamate-receptor).
Maltese: Fluralaner huwa inħibitur qawwi ta`partijiet tas-sistema nervuża tal-artropodi billi jaġixxi b`mod antagonistiku fuq il-kanali tal-chloride ligand-gate (GABA-receptor and glutamate-receptor).
English: The frequency of adverse reactions is defined using the following convention: - very common (more than 1 in 10 animals treated displaying adverse reaction(s)) - common (more than 1 but less than 10 animals in 100 animals treated) - uncommon (more than 1 but less than 10 animals in 1,000 animals treated) - rare (more than 1 but less than 10 animals in 10,000 animals treated) - very rare (less than 1 animal in 10,000 animals treated, including isolated reports).
Maltese: Il-frekwenza ta' effetti mhux mixtieqa hija definita skont din il-konvenzjoni: - komuni ħafna (aktar minn wieħed f'10 annimali ttrattati li juru effetti mhux mixtieqa matul ilperjodu ta' kura waħda) - komuni (aktar minn wieħed iżda inqas minn 10 annimali f'100 annimal ittrattati) - mhux komuni (aktar minn wieħed iżda inqas minn10 annimali f'1,000 annimal ittrattati) - rari (aktar minn wieħed iżda inqas minn10 annimali f'10,000 annimal ittrattati) - rari ħafna (inqas minn annimal wieħed f'10,000 annimal ttrattati, inklużi rapporti iżolati)
English: Butylhydroxytoluene 1.07 mg/ml Clear colourless to yellow solution.
Maltese: Butylhydroxytoluene 1.07 mg/ml
English: QUANTITY OF THE ACTIVE SUBSTANCE(S)
Maltese: TAS-SUSTANZA ATTIVA(I)
English: Pipette content (ml) Fluralaner (mg)
Maltese: Kontenut pipetta (ml)
English: Fluralaner is slowly eliminated from plasma (t1/2 = 15 days) and excreted in faeces and to a very low extent in urine.
Maltese: Fluranaler huwa eliminat bil-mod mill-plasma (t1/2 = 15 ġranet) u jitneħħa mal-feċi u f`limitu żgħir ħafna mill-urina.
English: Marketing authorisation holder: Intervet International B. V. Wim de Körverstraat 35
Maltese: Intervet International B. V.
English: For spot-on use.
Maltese: Għall-użu spot-on.
English: For the treatment of infestations with ear mites (Otodectes cynotis).
Maltese: Għat-trattament ta' infestazzjonijiet bid-dud tal-widnejn (Otodectes cynotis).
English: The following other adverse reactions were uncommonly observed in clinical trials shortly after administration: dyspnoea after licking the application site, hypersalivation, emesis, haematemesis, diarrhoea, lethargy, pyrexia, tachypnoea, mydriasis.
Maltese: Effetti mhux mixtieqa oħra kienu osservati mhux komuni fi provi kliniċi ftit wara l-amministrazzjoni: qtugħ ta`nifs wara tilgħaq is-sit tal-applikazzjoni, salvazzjoni eċċessiva, emesi, haematemesis, dijarea, letarġija, deni, tachypnoea, mydriasis.
English: The onset of effect (killing effect) for ticks (I. ricinus) and fleas (C. felis) is within 48 hours after treatment.
Maltese: Il-bidu tal-effett (effett li joqtol) għall-qurdien (I. ricinus) u briegħed (C.felis) huwa fi żmien 48 siegħa wara t-trattament.
English: Detailed information on this veterinary medicinal product is available on the website of the European Medicines Agency http://www.ema.europa.eu/.
Maltese: Informazzjoni dettaljata dwar dan il-prodott mediċinali veterinarju tinstab fuq il-websajt ta' lAġenzija Ewropea dwar il-Mediċini http://www.ema.europa.eu/.
English: Pregnancy, lactation and fertility:
Maltese: Tqala, treddigħ u fertilita:
English: Butylhydroxytoluene Dimethylacetamide Glycofurol
Maltese: Prekawzjonijiet speċjali għall-użu fl-annimali
English: Each pipette delivers:
Maltese: Detentur tal-awtorizzazzjoni għat-tqegħid fis-suq:
English: Therefore, during treatment with Bravecto Plus, other products that can inhibit p-glycoprotein (e.g. cyclosporine, ketoconazole, spinosad, verapamil) should only be used concomitantly according to the benefit-risk assessment of the responsible veterinarian.
Maltese: Għalhekk, waqt it-trattament b` Bravecto Plus, prodotti oħra li jistgħu jinhibixxu l-p-glycoprotein (e.g.cycosporins, ketoconazole, spinosad, verapamil) għandhom jintużaw flimkien biss wara valutazzjoni tal-veterinarju responsabbli skond il-benefiċċju - riskju.
English: Parasite control is recommended throughout the period of potential infestation risk.
Maltese: Kontroll tal-parassiti huwa rakomandat matul il-perjodu potenzjali ta` riskju ta` infestazzjoni.
English: No therapeutic effect against adult Dirofilaria immitis has been established.
Maltese: L-ebda effett terapewtiku ma ġie stabbilit kontra d-Dirofilaria immitis adult.
English: Milbemycins and avermectins have a common mode of action that is based on the binding of ligandgated chloride channels (glutamate-R and GABA-R).
Maltese: Milbemycins u avermectins għandom mod komuni ta`azzjoni li huwa bbażat fuq l-irbit mal- kanali talligand gated chloride (glutamate-R u GABA-r).
English: No adverse reactions were observed following topical administration to kittens aged 9-13 weeks and weighing 0.9-1.9 kg treated with overdoses of up to 5 times the maximum recommended dose (93 mg fluralaner + 4.65 mg moxidectin, 279 mg fluralaner + 13.95 mg moxidectin and 465 mg fluralaner + 23.25 mg moxidectin/kg body weight) on three occasions at shorter intervals than recommended (8week intervals).
Maltese: L-ebda effet mhux mixtieq ma ġie osservat wara applikazzjoni fuq il-ġilda lil frieħ ta` qattus ta`eta` 913 il-ġimgħa u li jiżnu 0.9-1.9 kg trattati b`doża eċċessiva sa 5 darbiet aktar mid-doża massima rakkomandata (93 mg fluralaner + 4.65 mg moxidectin, 279 mg fluralner + 13.95 mg moxidectin and 465 mg fluralaner + 23.25 mg moxidectin/kg piż tal-ġisem) fuq 3 okkażjonijiet f`intervalli iqsar minn dawk rakomandati (intervalli ta` 8-ġimgħat)
English: Bravecto Plus spot-on solution is available in three pipette sizes.
Maltese: Bravecto Plus soluzzjoni spot-on hija disponibbli fi tlett daqsijiet ta`pipetti.
English: No adverse reactions were observed following topical administration to kittens aged 9-13 weeks and weighing 0.9-1.9 kg treated with overdoses of up to 5 times the maximum recommended dose (93 mg fluralaner + 4.65 mg moxidectin, 279 mg fluralaner + 13.95 mg moxidectin and 465 mg fluralaner +
Maltese: L-ebda effet mhux mixtieq ma ġie osservat wara applikazzjoni fuq il-ġilda lil frieħ ta` qattus ta`eta` 913 il-ġimgħa u li jiżnu 0.9-1.9 kg trattati b`doża eċċessiva sa 5 darbiet aktar mid-doża massima rakkomandata (93 mg fluralaner + 4.65 mg moxidectin, 279 mg fluralner + 13.95 mg moxidectin and
English: UNITED KINGDOM
Maltese: L-Olanda
English: for small cats 1.2 - 2.8kg for medium-sized cats >2.8 - 6.25 kg for large cats >6.25 - 12.5 kg
Maltese: għal qtates żgħar 1.2 - 2.8 kg għal qtates daqs medju >2.8 - 6.25 kg għal qtates kbar >6.25 - 12.5 kg
English: Butylhydroxytoluene 1.07 mg/ml For the full list of excipients, see section 6.1.
Maltese: Għal-lista sħiħa tal-ingredjenti (mhux attivi), ara s-sezzjoni 6.1.
English: It is efficacious against ticks (Ixodes ricinus), fleas (Ctenocephalides felis) and ear mites (Otodectes cynotis) on the cat.
Maltese: Huwa effikaċi kontra qurdien (Ixodes ricinus), briegħed
English: Moxidectin is only active on larvae (L3 and L4) of Dirofilaria immitis and not on adult worms.
Maltese: Moxidectin huwa attiv biss fuq larvi (L3 u L4) tad
English: EU/2/18/224/001 (112.5 mg + 5.6 mg, 1 pipette) EU/2/18/224/002 (112.5 mg + 5.6 mg, 2 pipettes) EU/2/18/224/003 (250 mg + 12.5 mg, 1 pipette) EU/2/18/224/004 (250 mg + 12.5 mg, 2 pipettes) EU/2/18/224/005 (500 mg + 25 mg, 1 pipette) EU/2/18/224/006 (500 mg + 25 mg, 2 pipettes)
Maltese: FIS-SUQ EU/2/18/224/001 (112.5 mg + 5.6 mg, 1 pipetta)
English: Oral uptake of the product at the maximum recommended dose of 93 mg fluralaner + 4.65 mg moxidectin/kg body weight induced some self-limiting salivation or single incidences of vomiting immediately after administration.
Maltese: Teħid mil-ħalq tal-prodott fid-doża massima rakomandata ta` 93mg fluralaner + 4.65mg moxidectin/kg piż tal-ġisem indotat salivazzjoni limitata jew episoju singolu ta` remettar immedjatament wara l-amministrazzjoni.
English: The cap will stay on the pipette; it is not possible to remove it.
Maltese: Ittapp jibqa' fuq il-pipetta; mhumiex possibli li tneħħieħ.
English: The pharmacokinetic profiles of fluralaner and moxidectin are not affected by co-administration.
Maltese: Il-profili tal-farmakokinetika tal-fluralaner u moxidectin m`humiex affetwati meta jinataw flimkien.
English: Special precautions for use in animals:
Maltese: Kodici ATĊ veterinarja:
English: For the treatment of infections with ear mites (Otodectes cynotis) or the gastrointestinal nematodes T. cati and A. tubaeforme, the need for, and the frequency of, re-treatment as well as the choice of the treatment (monosubstance or combination product) should be evaluated by the prescribing veterinarian.
Maltese: Għall- trattament ta` infezzjonijiet bid-dud tal-widnejn (Otodectes cynotis) jew bin-nematodi gastrointestinali T.cati u A. tubaeforme , il-ħtieġa, u l-`frekwenza, re-trattament kif ukoll l-għażla tat trattament (sustanza waħidha jew taħlita ta`prodotti) għandha tiġi evaluata mill-veterinarju.
English: The following table defines the size of pipette to be used according to the body weight of the cat (corresponding to a dose of 40-94 mg fluralaner/kg body weight and 2-4.7 mg moxidectin/kg body weight):
Maltese: It-tabella li ġejja tidifenixxi d-daqs tal-pipetta li għandha tintuża skond il-piż tal-ġisem tal-qattus (tikorrispondi għal doża ta` 40-94mg fluralaner/kg piż tal-ġisem u 2-4.7 mg moxidectin/kg piż tal-ġisem):
English: Pipette size to be used
Maltese: Kull pipetta tipprovdi:
English: Bravecto Plus 112.5 mg / 5.6 mg spot-on solution for small cats (1.2 - 2.8 kg) Bravecto Plus 250 mg / 12.5 mg spot-on solution for medium-sized cats (>2.8 - 6.25 kg) Bravecto Plus 500 mg / 25 mg spot-on solution for large cats (>6.25 - 12.5 kg) fluralaner / moxidectin
Maltese: Bravecto Plus 112.5 mg / 5.6 mg soluzzjoni spot-on għal qtates żgħar (1.2 - 2.8 kg) Bravecto Plus 250 mg / 12.5 mg soluzzjoni spot-on għal qtates daqs medju (>2.8 - 6.25 kg) Bravecto Plus 500 mg / 25 mg soluzzjoni spot-on għal qtates kbar (>6.25 - 12.5 kg) fluralaner/moxidectin
English: Excipient(s):
Maltese: Sustanza mhux attiva(i):
English: Seek further veterinary examination (i.e. otoscopy) 28 days after treatment to determine whether there is re-infestation requiring additional treatment.
Maltese: Fittex vista medika veterinarja oħra (i.e. otoskopija) 28 ġurnata wara t-trattament biex ikun iddeterminat hemmx infestazzjoni mill-ġdid li għandha bżonn trattament ieħor.
English: Bravecto Plus 112.5 mg / 5.6 mg spot-on solution for small cats (1.2 - 2.8 kg) Bravecto Plus 250 mg / 12.5 mg spot-on solution for medium-sized cats (>2.8 - 6.25 kg) Bravecto Plus 500 mg / 25 mg spot-on solution for large cats (>6.25 - 12.5 kg)
Maltese: Bravecto Plus 112.5 mg / 5.6 mg soluzzjoni spot-on għal qtates żgħar (1.2 - 2.8 kg) Bravecto Plus 250 mg / 12.5 mg soluzzjoni spot-on għal qtates daqs medju (>2.8 - 6.25 kg) Bravecto Plus 500 mg / 25 mg soluzzjoni spot-on għal qtates kbar (>6.25 - 12.5 kg)
English: Weight of cat (kg)
Maltese: Piż tal-qattus (kg)
English: Unit dose pipette made of laminated aluminium/polypropylene foil closed with a high-density polyethylene (HDPE) cap and packed in a laminated aluminium foil sachet.
Maltese: Pipetta ta`doża waħda magħmula minn folja laminata tal-aluminju/polypropylene magħluqa b`tapp ta` polyethylene b`densita għolja u ppakjata f`qartas tal-aluminju laminat.
English: Rue de Lyons
Maltese: U L-UŻU
English: For the treatment of tick and flea infestations in cats providing immediate and persistent flea (Ctenocephalides felis) and tick (Ixodes ricinus) killing activity for 12 weeks.
Maltese: Għat-trattament ta` infestazzjonijiet tal-qurdien u briegħed fil-qtates, jipprovdi qtil immedjat u persistenti tal- briegħed (Ctenocephalides felis) u qurdien (Ixodes ricinus) għall 12 il-ġimgħa.
English: Bravecto Plus 112.5 mg + 5.6 mg spot-on solution for small cats Bravecto Plus 250 mg + 12.5 mg spot-on solution for medium-sized cats Bravecto Plus 500 mg + 25 mg spot-on solution for large cats
Maltese: Daqs tal-pipetta li għandha tintuża Bravecto Plus 112.5 mg + 5.6 mg soluzzjoni spot-on għal qtates żgħar Bravecto Plus 250 mg + 12.5 mg soluzzjoni spot-on għal qtates medji Bravecto Plus 500 mg + 25 mg soluzzjoni spot-on għal qtates kbar
English: For cats with, or at risk from, mixed parasitic infestations by ticks or fleas and ear mites, gastrointestinal nematodes or heartworm.
Maltese: Għal qtates bi jew f`riskju ta`infestazzjoni parassitarja mħalta b`qurdien jew briegħed u dud talwidnejn, nematodi gastrointestinali jew heartworm.
English: Therefore prior to application of Bravecto Plus for the concurrent prevention of infection with adult D. immitis, the advice provided in section 4.4 should be considered.
Maltese: Għalhekk qabel tapplika l-Bravecto Plus għall-prevenzjoni tal-infezzjoni kurrenti bid- D.immitisadult, il-parir provdut f`sezzjoni 4.4 għandu jiġi kunsidrat.
English: This leads to an increased membrane permeability of nematode and arthropod nerve and/or muscle cells for chloride ions and results in hyperpolarization, paralysis and death of the parasites.
Maltese: Dan iwassal għal permeabilita`akbar fil-membrani taċ-celloli nervużi u/jew muskulari tan-nematodi u artropodi għall- ijoni tal-klorajd li jirriżulta f`iperpolarizzazzjoni, paraliżi u mewt tal-parassita.
English: For the concurrent treatment of infections with the gastrointestinal nematodes T. cati and A. tubaeforme, a single dose of the product should be applied.
Maltese: Għal trattament fl-istess ħin ta` infezzjonijiet ta` nemotodi gastrointestinali T.cati u A.tubaeforme flimkien, doża waħda tal-prodott għandha tiġi applikata.
English: Apply to skin.
Maltese: U LUŻU
English: CLINICAL PARTICULARS 4.1 Target species
Maltese: KLINIKU 4.1 Speċi li fuqhom ser jintuża l-prodott
English: Cats in areas endemic for heartworm (or those which have travelled to endemic areas) may be infected with adult heartworms.
Maltese: Qtates f`żoni endemiċi tal-heartworm (jew dawk li vjaġġaw f`żoni endemiċi) jistgħu jkunu infettati bil-heartworm adult.
English: • allergy
Maltese: • allerġija
English: Section 4 “Possible side effects”
Maltese: Sezzjoni 4 “Effetti sekondarji possibli”
English: • depression (e.g. citalopram, escitalopram)
Maltese: • depressjoni (eż. citalopram, escitalopram)
English: • bacterial infections (e.g. the antibiotics erythromycin, moxifloxacin, levofloxacin)
Maltese: • Infezzjoni batterjali (eż. L-antibijotiċi erythromycin, moxifloxacin, levofloxacin)
English: • cancer (e.g. toremifene, vandetanib)
Maltese: • kanċer (eż. toremifene, vandetanib)
English: Co-administration of hydroxyzine with drugs known to prolong the QT interval and/or induce Torsade de Pointes e.g. class IA (e.g. quinidine, disopyramide) and III antiarrhythmics (e.g. amiodarone, sotalol), some antihistamines, some antipsychotics (e.g. haloperidol), some antidepressants (e.g. citalopram, escitalopram), some antimalarial drugs (e.g. mefloquine), some antibiotics (e.g. erythromycin, levofloxacin, moxifloxacin), some antifungal agents (e.g. pentamidine), some gastro-intestinal medicines (e.g. prucalopride), some medicines used in cancer (e.g., toremifene, vandetanib), methadone, increase the risk of cardiac arrhythmia.
Maltese: It-teħid flimkien ta' hydroxyzine ma' mediċini li huma magħrufa li jtawlu l-interval QT u/jew jagħmlu induzzjoni ta' Torsade de Pointes eż. klassi IA (eż. quinidine, disopyramide) u mediċini anti-arritmiċi III (eż. amiodarone, sotalol), xi anti-istamini, xi antipsikotiċi (eż. haloperidol), xi antidepressanti (eż. citalopram, escitalopram), xi mediċini kontra il-malarja (eż. mefloquine), xi antibiotiċi (eż. erythromycin, levofloxacin, moxifloxacin), xi mediċini antifungali (eż. pentamidine), xi mediċini gastro-intestinali (eż. prucalopride), xi mediċini użati fil-kanċer (eż. toremifene, vandetanib), methadone, żieda fir-riskju ta' arrythmias tal-qalb.
English: • psychoses (e.g. haloperidol)
Maltese: • psikożi (eż. haloperidol)
English: • malaria (e.g. mefloquine)
Maltese: • malarja (eż. mefloquine)
English: • gastro-intestinal disorders (e.g. prucalopride)
Maltese: • mard gastro-intestinali (eż. prucalopride)
English: Do not <take> <use> X
Maltese: <Tiħux> <Tużax> X